HOME >> MEDICINE >> NEWS
Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer

CHICAGO, June 2, 2007 -- ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer , according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Results from a Phase III study suggest that a first-line ALIMTA-based regimen may deliver less toxicity than a commonly used therapy in advanced non-small cell lung cancer (NSCLC). ALIMTA is manufactured and marketed by Eli Lilly and Company.

A prospective, randomized, multicenter Phase III study was conducted to compare ALIMTA plus carboplatin with the commonly used regimen of GEMZAR (gemcitabine HC1 for injection) plus carboplatin (ASCO Abstract # 7517 ). The study, conducted by the Norwegian Lung Cancer Group, enrolled 446 chemonave patients with either stage IIIB or IV NSCLC. The primary purpose of the study was to evaluate if the ALIMTA-carboplatin combination provided increased quality-of-life benefits while offering comparable survival data. As such, the primary endpoint was quality of life (defined in the study as nausea/vomiting; dyspnea or a difficulty in breathing, and; fatigue) and the secondary endpoint was overall survival.

Thus far, 384 patients have been analyzed for toxicity and there were fewer patients in the ALIMTA arm who experienced Grade 3/4 thrombocytopenia or a low platelet level (48 vs. 107, p<.001); leukopenia or a lowering of leukocyte white blood cells (44 vs. 89, p<.001), and; granulocytopenia or a lowering of granulocyte white blood cells (78 vs. 98, p=.02). More patients in the GEMZAR arm received transfusion of platelets (5 vs. 19, p=.02). At this point, no difference in survival has been observed.

The patients in this study received a comparable quality-of-life benefit whether they received ALIMTA and carboplatin or GEMZAR and carboplatin, said Bjrn Henning Grnberg, M.D. of St. Olavs University Hospital in Norway and the studys principal investigat
'"/>

Contact: Neil Hochman
n.hochman@cprworldwideusa.com
212-453-2067
CPR Worldwide
2-Jun-2007


Page: 1 2 3

Related medicine news :

1. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
2. Clinical review -- A psychological approach to the management of irritable bowel syndrome
3. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
4. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
5. Clinical guidelines for blood conservation during cardiac procedures developed
6. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
7. Clinical trial coordinators need more financial conflict-of-interest training
8. Clinical studies evaluate potential treatments for mouth ulcers
9. NIH names Clinical Trial Units for the Microbicide Trials Network
10. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
11. Study in recent issue of Clinical Pediatrics helps pediatricians to understand discipline practices

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... ... will be held Wednesday, April 7, to Saturday, April 10, 2021, at Wynn ... Spa Show is a national trade show for non-invasive medical aesthetic practices that ...
(Date:9/1/2020)... ... September 01, 2020 , ... KitoTech Medical, ... convertible note financing, which will be used to accelerate the commercialization of its ... financing, the company will continue to expand its customer base of healthcare systems ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... the 10th Anniversary of Blood Cancer Awareness Month (BCAM) and its international ...
(Date:8/31/2020)... Colo. (PRWEB) , ... August 31, 2020 , ... ... provider of innovative higher-learning opportunities through high-quality, career-relevant, and affordable online education – ... Responder Psychology . , Among the first of its kind in the ...
(Date:8/31/2020)... ... August 31, 2020 , ... Dr. Chang has ... with autism and other developmental disabilities, as well as supporting staff in caring ... with autism, school consultation, and staff development. She joined the company in 2015 ...
Breaking Medicine News(10 mins):
(Date:8/27/2020)... (PRWEB) , ... August 27, 2020 , ... ... analytics, has partnered with Enquire, a leading provider of cloud CRM, marketing automation, ... two organizations' strategic partnership will involve the integration of Trella’s performance intelligence data ...
(Date:8/26/2020)... CHARLES, Mo. (PRWEB) , ... ... ... Services, a member of Eurofins BioPharma Services, Laboratory Testing division, expands its ... the existing suite of Flow Cytometry platforms available. With industry-leading biomarker solutions, ...
(Date:8/26/2020)... ... ... Hero Life Sciences announced today that it will be setting ... face masks and N95 respirators in its manufacturing plant located in the City of ... are facing in trying to find quality disposable face masks during the COVID-19 pandemic ...
Breaking Medicine Technology:
Cached News: